Directory of funded grants

Filter by

586 results found

Does psilocybin increase synaptic density in the brain in patients with mild cognitive impairment?

  • Grant Type

    Capacity building grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    Alzheimer Society Research Program (ASRP)

  • Province

    Ontario

  • Start Date

    2024

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

Amnestic mild cognitive impairment (aMCI) is viewed as a precursor to Alzheimer’s Disease (AD) for which there are no effective treatments. Evidence suggests that psilocybin exerts its psychedelic, and possibly its clinical effects, through activating cellular serotonin receptors in the brain. Intriguingly, reduced serotonin receptor density in the brain is…

Project Ongoing

See the project and researchers

Genes involved in APP-mediated GLUT1 regulation

  • Grant Type

    Capacity building grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    Alzheimer Society Research Program (ASRP)

  • Province

    Québec

  • Start Date

    2024

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

Alzheimer’s disease is the most common form of dementia. The brains of many of the patients are less well supplied with glucose (sugar), but not much research aims to understand why this happens. Further, a protein of central importance to Alzheimer’s disease is APP. My lab found that there may…

Project Ongoing

See the project and researchers

Targeting the microbiota-gut-brain axis with diet and exercise interventions in individuals with subjective cognitivedecline

  • Grant Type

    Capacity building grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    Alzheimer Society Research Program (ASRP)

  • Province

    Ontario

  • Start Date

    2024

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Project Overview

Individuals with or at increased risk of Alzheimer’s disease (AD) have an altered community of microbes(microbiome) within the intestinal tract. Through the production of inflammatory and neurotoxic metabolites, this microbial population may negatively contribute to cognitive decline and early dementia risk. Lifestyle interventions, such as diet and exercise, have been…

Project Ongoing

See the project and researchers

MicroRNA biomarkers: Using Tears to Assess Alzheimer’s Disease

  • Grant Type

    Capacity building grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    Alzheimer Society Research Program (ASRP)

  • Province

    British Columbia

  • Start Date

    2024

  • Total Grant Amount

    $10,000

  • Health Canada Contribution

    $50,000

Project Overview

Alzheimer’s disease (AD) is the most common form of dementia and 7th leading cause of death in North-America. It affects memory, thinking and behavior, thus causing major challenges to patients, families, society, and healthcare systems. Today, diagnosis requires expensive radioactive brain scans or spinal fluid markers obtained through harmful procedures.…

Project Ongoing

See the project and researchers

Evaluating the histone variant macroH2A1.1 as a master regulator of PARP1-Sirt1 balance in Alzheimer’s disease

  • Grant Type

    Capacity building grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    Alzheimer Society Research Program (ASRP)

  • Province

    Ontario

  • Start Date

    2024

  • Total Grant Amount

    $10,000

  • Health Canada Contribution

    $50,000

Project Overview

Alzheimer’s Disease (AD) is characterized by memory decline and neuronal pathology, including amyloid β (Aβ)plaques and oxidative stress. These markers are influenced by PARP1, which propagates cellular damage, and Sirt1, which protects against cellular damage. PARP1 becomes hyperactive in AD and inhibits Sirt1, thus propagating neuronal damage and memory decline.…

Project Ongoing

See the project and researchers